Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Axitinib Disappoints As RCC Adjuvant Therapy

Executive Summary

An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.

You may also be interested in...



Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer

SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk and evaluating patients with left-sided colorectal cancer.

Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.

Pipeline Watch: Phase III Readouts In Eosinophilic Esophagitis, Myasthenia Gravis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

WI964844

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel